Endoplasmic reticulum stress inhibitors, chronic kidney disease prevention and improvement agents, and foods.

Triglycerides rich in pentadecanoic acid address the limitations of conventional foods and drugs by inhibiting endoplasmic reticulum stress, effectively preventing and improving chronic kidney disease through reduced cell death and protein accumulation.

JP7954119B2Active Publication Date: 2026-11-19REFINE HLDG CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2023094181
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-06-07
Publication Date
2026-11-19
Estimated Expiration
2043-06-07

AI Technical Summary

Technical Problem

Conventional foods and beverages lack the ability to suppress endoplasmic reticulum stress, prevent protein denaturation, and alleviate chronic kidney disease, while existing therapeutic agents have side effects and are not suitable for long-term use.

Method used

Triglycerides composed mainly of saturated fatty acids, particularly pentadecanoic acid, are used to inhibit endoplasmic reticulum stress and prevent or ameliorate chronic kidney disease by reducing cell death and protein accumulation.

Benefits of technology

The triglycerides effectively suppress endoplasmic reticulum stress, reducing cell death and improving renal function, providing a long-term solution for chronic kidney disease prevention and symptom alleviation without significant side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007954119000006
    Figure 0007954119000006
  • Figure 0007954119000007
    Figure 0007954119000007
  • Figure 0007954119000001
    Figure 0007954119000001
Patent Text Reader

Abstract

To provide endoplasmic reticulum stress inhibitors that are safe for long-term consumption and applicable as a food, beverage, or medication for prevention, symptom mitigation, or improvement, and also to provide preventive and improvement agents for diseases manifested through podocyte death.SOLUTION: A composition contains a triglyceride represented by formula (I) (where R1, R2 and R3 each represent a saturated fatty acid residue, where at least one thereof is a pentadecanoic acid residue) as an active ingredient.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to an endoplasmic reticulum (ER) stress inhibitor for improving the state of ER stress. Furthermore, the present invention relates to agents for preventing, improving, and treating diseases whose onset is associated with ER stress, particularly to agents for preventing and improving chronic kidney disease, and to foods containing these agents. [Background technology]

[0002] Endoplasmic reticulum (ER) stress is a condition in which cells, exposed to various internal or external environmental changes, experience abnormal expression of the protein synthesis system within the ER lumen, leading to an increase in protein levels. This accumulation of proteins that cannot be properly eliminated results in the accumulation of defective proteins that do not fold correctly. Factors that cause ER stress include nutrient starvation, disruption of intracellular calcium concentration, hypoxia, expression of mutant proteins, and viral infection. When ER stress occurs, cells activate lipid synthesis and expand the ER to increase their protein folding capacity in order to maintain homeostasis. In stages where the accumulation of defective proteins is relatively minor, the ER stress response, a response mechanism to eliminate defective proteins, is performed. However, if the stress state is severe or persists for a long period, denatured proteins accumulate in the ER, leading to adverse effects on the cell. To avoid damage from ER stress and maintain homeostasis, cells induce apoptosis (programmed cell death) in tissues and organs throughout the body.

[0003] Chronic kidney disease (CKD) is a relatively common chronic progressive disease characterized by a condition in which either a decline in renal function or an initial finding suggesting renal dysfunction, or both, persists for three months or more. The number of people with CKD is estimated to be around 13.3 million among Japanese adults (Non-Patent Literature 1). Furthermore, CKD increases with age, and the prevalence of CKD among the elderly exceeds approximately 30%, making it a new national disease attracting attention (Non-Patent Literature 1). As CKD progresses, treatments such as hemodialysis become necessary, and it is important to take measures to prevent the disease from becoming severe before hemodialysis is initiated. Endoplasmic reticulum stress is known to be involved in the onset of CKD. To date, dietary therapies such as salt restriction, protein restriction, and potassium restriction have been implemented as adjuncts to prevent the progression of chronic kidney disease (CKD) through food. While improvements in CKD have been reported with lactoferrin, a type of milk protein, and its hydrolysates (see Patent Document 1), D-serine (see Patent Document 2), D-alanine (see Patent Document 3), and lipids derived from herbs (see Patent Document 4), the extent of their effects remains unknown and is not considered sufficient.

[0004] Furthermore, drugs that treat the underlying cause include corticosteroids used when there is inflammation of the kidneys, such as in chronic glomerulonephritis; immunosuppressants used when the cause is thought to be a deduction disorder; and antiplatelet and anticoagulant drugs that improve blood flow and reduce the burden on the kidneys (see Non-Patent Literature 2). However, while these drugs can provide temporary therapeutic effects, their long-term use is difficult due to side effects, and they are not currently sufficient. [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Japanese Society of Nephrology (ed.): CKD Treatment Guidelines 2012, Tokyo Medical Publishing Co., Ltd. (2012) [Non-Patent Document 2] Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998 Dec;9(12 Suppl):S16-23.)

Patent Documents

[0007]

Patent Document 1

Patent Document 2

Patent Document 3

Patent Document 4

Summary of the Invention

Problem to be Solved by the Invention

[0008] Among conventional foods and beverages, no foods and beverages have been known that suppress cell death via endoplasmic reticulum stress reduction and suppression action, prevent or ameliorate protein denaturation, and suppress abnormal proteins. In addition, conventional therapeutic agents for kidney diseases have problems such as side effects. For this reason, foods, beverages and pharmaceuticals that can be taken for a long period of time for prevention, symptom alleviation and amelioration are desired. Accordingly, the problem to be solved by the present invention is to provide an endoplasmic reticulum stress inhibitor, a prophylactic, progression-preventing and ameliorating agent for chronic kidney disease, and a food product, which can be used as foods, beverages and pharmaceuticals suitable for such applications.

Means for Solving the Problem

[0009] As a result of intensive studies to solve the above problems, the present inventors found that triglycerides composed of saturated fatty acids mainly containing pentadecanoic acid (C15) (pentadecanoic acid triglyceride: hereinafter sometimes referred to as "PdATG") act on renal glomerular cells, suppress the accumulation of denatured proteins in the endoplasmic reticulum caused by stress damage, and reduce the resulting cell death (apoptosis), thereby effectively preventing or ameliorating chronic kidney disease, and have completed the present invention.

[0010] The endoplasmic reticulum stress inhibitor according to the first aspect of the present invention for solving the above problems is represented by the following formula (I):

[0011]

Chemical Formula

[0012] (In the formula, R 1 , R 2 and R 3 are each a saturated fatty acid residue, at least one of which is a pentadecanoic acid residue.) The triglyceride represented by this is contained as an active ingredient.

[0013] In one embodiment of this endoplasmic reticulum stress inhibitor, the triglyceride of formula (I) preferably has R 1 and R 2 or R 1 and R 3 as pentadecanoic acid residues. In another embodiment, any one of R 1 , R 2 and R 3 may be a tridecylic acid residue (C13), myristic acid residue (C14), palmitic acid residue (C16) or margaric acid residue (C17).

[0014] In still another preferred embodiment, the triglyceride of the above formula (I) in which all of R 1 , R 2 and R 3 are pentadecanoic acid residues, and R 1 , R2 and R 3 A triglyceride of formula (I) in which any two of the residues are pentadecanoic acid residues and the other one is a myristic acid or palmitic acid residue may also be included.

[0015] In yet another preferred embodiment of the endoplasmic reticulum stress inhibitor of the present invention, the triglyceride of formula (I) is derived from algae of the genus Aurantiochytrium or Schizochytrium, where R 1 , R 2 and R 3 Each of these may be a triglyceride, wherein each is a saturated fatty acid residue, at least one of which is a pentadecanoic acid residue. Furthermore, the mixture may contain unsaturated fatty acids derived from algae of the genus Aurantiochytrium or Schizochytrium.

[0016] In a second aspect of the present invention, an agent for preventing and improving glomerular dysfunction in chronic kidney disease is provided, comprising a triglyceride represented by the above formula (I) as an active ingredient.

[0017] In a third aspect of the present invention, a food product containing a triglyceride represented by formula (I) as an active ingredient is provided. This food product is preferably used, for example, as a health food, a functional food, or a food for specified health uses, to improve the daily lives of people who are prone to swelling and fatigue. [Effects of the Invention]

[0018] The endoplasmic reticulum stress inhibitor according to the present invention can suppress endoplasmic reticulum stress in mammalian cells, particularly renal bulbs, and can provide long-term use of food, beverages, or pharmaceuticals for prevention, symptom reduction, and improvement. [Brief explanation of the drawing]

[0019] [Figure 1]This figure shows the details of an experiment in which changes in glomerular area due to added drugs were investigated in an animal model of CKD and a control group in one embodiment of the present invention. (A) is a micrograph of a glomerular section after the test period, and (B) is a graph showing the area of ​​the glomerulus. [Figure 2] This figure shows the details of an experiment in which changes in renal function due to added drugs were investigated in an animal model of CKD and a control group in one embodiment of the present invention, where (A) is a graph showing BUN values ​​and (B) is a graph showing Cre values. [Modes for carrying out the invention]

[0020] Next, the present invention will be described in more detail based on embodiments. It should be noted that the embodiments described below are not intended to limit the invention as defined in the claims, and not all of the elements and combinations thereof described in each embodiment are necessarily essential to the solution of the present invention.

[0021] (Active ingredients) In this specification, PdATG means an ester of at least one pentadecanoic acid and glycerol, represented by the following formula (I) R 1 , R 2 and R 3 At least one of, preferably any two of, for example, R 1 and R 2 or R 1 and R 3 However, R is more preferably 1 , R 2 and R 3 The triglyceride contains three pentadecanoic acid residues. The pentadecanoic acid may be attached to any of the 1st, 2nd, or 3rd positions on the glyceride.

[0022] [ka]

[0023] (In the formula, R 1 , R 2 and R 3Each of these is a saturated fatty acid residue, and at least one of them is a pentadecanoic acid residue.

[0024] In the formula, R 1 , R 2 and R 3 Any one of the residues represented by may be a saturated fatty acid residue other than a pentadecanoic acid residue. "Saturated fatty acid" is a general term for fatty acids that do not have double or triple bonds in their molecule, C n H 2n+1 It is represented by the chemical formula COOH. These saturated fatty acids are linear or branched saturated fatty acids, including linear saturated fatty acids such as capric acid (C10), lauric acid (C12), tridecyl acid (C13), myristic acid (C14), pentadecanoic acid (C15), palmitic acid (C16), margaric acid (C17), stearic acid (C18), arachidic acid (C20), behenic acid (C22), lignoceric acid (C24), and cerotic acid (C26), as well as branched saturated fatty acids such as 2-hexyldecanoic acid (C16), 13-methylpentadecanoic acid (C16), and 16-methylheptadecanoic acid (C18).

[0025] In a preferred embodiment, PdATG is R 1 , R 2 and R 3 The triglyceride of formula (I) above, in which all are pentadecanoic acid residues, and R 1 , R 2 and R 3 The mixture contains both triglycerides in which any two of the residues are pentadecanoic acid residues and the other one is a myristic acid or palmitic acid residue. The ratio of the two in this mixture is not particularly limited, but is preferably 1:2 to 2:1 by mass, and more preferably approximately 1:1. Furthermore, each of these is present in an amount of 10% by mass or more, preferably 20% by mass or more, relative to the total amount of triglycerides. Moreover, it is more preferable that the mixture of triglycerides containing two or more pentadecanoic acid residues is present in an amount of 50% by mass or more of the oil and fat.

[0026] In a more preferred embodiment, PdATG is represented by the following formula (II) or (III).

[0027] [ka]

[0028] (However, in formulas (II) and (III) above, R is a saturated fatty acid of C14 to C16.) It is more preferable that a mixture of triglycerides containing two or more residues of pentadecanoic acid is present in an amount of 50% by mass or more in the oil and fat, but even if the content of triglycerides containing two or more residues of pentadecanoic acid is 50% by mass or less, the objective can be achieved by increasing the intake amount. Therefore, the active ingredient of the present invention may exist in the form of a mixture of triglycerides containing two or more residues of pentadecanoic acid, and the mixture itself can function as an active ingredient if it is present with a purity of at least 1% by mass, preferably 50% by mass or more, and more preferably 90% by mass or more, relative to the total amount of triglycerides.

[0029] The active ingredient of the present invention may exist in a mixture with triglycerides other than the compound of formula (I), and the mixture itself can function as an active ingredient if it is present with a purity of at least 1% by mass, preferably 50% by mass or more, and more preferably 90% by mass or more, relative to the total amount of triglycerides.

[0030] The active ingredient of the present invention has at least one, preferably two or more, odd-chain fatty acids, particularly pentadecanoic acid, in its molecule. Therefore, it is believed that ingesting it suppresses the accumulation of abnormal proteins in the endoplasmic reticulum due to endoplasmic reticulum stress, as described later, thereby reducing cell death and restoring normal function.

[0031] (Effects and Benefits) The active ingredient of this invention has the effect of improving diseases caused by endoplasmic reticulum stress and pre-disease physical conditions by alleviating endoplasmic reticulum stress in various cells. The kidneys are called "silent organs" because often no obvious symptoms appear until the condition worsens, and even when glomerular filtration function is impaired, there may be almost no noticeable symptoms. By the time the abnormality becomes clear and symptoms are noticed, glomerular filtration function may have already decreased to nearly half of what it was in a healthy state. CKD is known to cause various complications, and in patients whose disease has progressed to the point where hemodialysis is required, the risk of developing cardiovascular diseases such as heart failure and cerebrovascular disease is significantly higher, with a relative risk of 10-30 compared to community-dwelling elderly people (Non-Patent Literature 2). Furthermore, it has been reported that hemodialysis patients have a higher risk of physical and cognitive decline, and the impact on life expectancy and ADL / QOL decline has been pointed out. Early detection and prevention of progression of CKD in the elderly are important, and this means that establishing preventive measures well before the onset of the disease is extremely important. Furthermore, it is important to prevent the progression of CKD by taking preventative and mitigating ingredients before the onset of symptoms, and at the same time, to treat it from the early stages when the onset is suspected.

[0032] CKD can be detected by assessing glomerular filtration function by examining the amount of protein in the urine and creatinine in the blood. Creatinine is one of the waste products in the blood; normally, it is filtered by the kidneys and most of it is excreted in the urine. However, when glomerular filtration function declines, it is not excreted in the urine and accumulates in the blood. This creatinine in the blood is called the serum creatinine level and is an indicator used in clinical practice. Furthermore, a decline in kidney function can also be detected by measuring blood urea nitrogen (BUN), which is the amount of nitrogen contained in the blood. Urea nitrogen is a waste product produced after protein is utilized. Normally, it is filtered by the glomeruli of the kidneys and excreted in the urine, but when kidney function declines, it cannot be filtered completely and accumulates in the blood, resulting in a high blood urea nitrogen level. These are the main ways in which glomerular function and kidney function are assessed.

[0033] (Kidney disease and endoplasmic reticulum stress) Endoplasmic reticulum (ER) stress progresses due to environmental factors such as aging, genetic factors, and lifestyle, and insufficient repair gradually leads to loss of homeostasis and cell death. Age-related diseases can be described as conditions in which ER progresses abnormally due to the combination of internal and external factors, and characteristic diseases occur in each organ. It has become clear that glomerular epithelial cell damage plays an important role in the progression of glomerular damage in the kidney, regardless of the present disease, and it is being proposed that ER stress is involved (Yang Guochang, Special Feature: Nephrotic Syndrome - Elucidation of the Mechanism of Glomerular Epithelial Cell Damage - From the Perspective of ER Stress - Japanese Journal of Nephrology 49(2), 72-76). It has become clear that medicines and food components that can actually improve ER stress are essential for maintaining people's health.

[0034] (Method for producing triglyceride mixtures) The triglyceride mixture, which is the active ingredient of the present invention, may be chemically synthesized or naturally occurring. If it is naturally occurring, its source is not particularly limited. Examples include lipids produced by organisms in their bodies, such as the fats of livestock and poultry, the oils and fats of fish and shellfish, vegetable oils, or lipid-producing microorganisms. From the viewpoint of industrial productivity, microorganisms such as algae, bacteria, fungi (including yeast), and / or protists are preferred. Preferred microorganisms include those selected from the group consisting of golden algae (microorganisms of the stramenopil kingdom, etc.), green algae, diatoms, dinoflagellates, yeasts, and fungi of the genera Mucor and Mortierella. The members of the microbial group stramenopil include microalgae. Microalgae are defined as organisms with a cell size of 1 μm to 100 μm in diameter, which are the remaining organisms from among photosynthetic organisms that produce oxygen, excluding mosses, ferns, and seed plants. Labyrinthulae, which are protists closely related to microalgae, are also included. Labyrinthuli are heterotrophic marine eukaryotic microorganisms that do not perform photosynthesis and are widely distributed mainly in subtropical and tropical regions. Generally, Labyrinthuli are broadly classified into the families Labyrinthulidae and Thraustochytriidae, and include genera such as Labyrinthula, Aurantiochytrium, Schizochytrium, Thraustochytrium, Aplanochytrium, oblongichytrium, Botryochytrium, and Japonochytrium.

[0035] Among the Labyrinthula species to be cultured, Aurantiochytrium, Schizochytrium, or Slaustchytrium genera are more preferable. These species have relatively high lipid production capabilities and can produce hydrocarbons such as squalene, making them suitable for use in food products and as raw materials for biofuels.

[0036] Labyrinthura can be cultured using any of the following methods: batch culture, continuous culture, or fed-batch culture. Furthermore, Labyrinthura can be cultured using any appropriate culture method, such as shaking culture, aeration culture, aeration-stirred culture, air-lift culture, or static culture. Among these culture methods, aeration-stirred culture or air-lift culture is more preferred. Culture apparatus used for culturing Labyrinthura can include, for example, mechanically agitated reactors, air-lift reactors, packed-bed reactors, and fluidized-bed reactors. Various containers such as tanks, jar fermenters, flasks, dishes, culture bags, tubes, and test tubes can be used as culture vessels, depending on the purpose of cultivation and the required culture volume. Culture vessels may be made of appropriate materials, such as inorganic materials like stainless steel and glass, or organic materials like polystyrene, polyethylene terephthalate copolymer, and polypropylene.

[0037] Labyrinthula can be cultured under appropriate temperature, pH, and aeration conditions. The culture temperature is preferably between 5°C and 40°C, more preferably between 10°C and 35°C, and even more preferably between 10°C and 30°C. The pH is preferably between 2 and 11, more preferably between 4 and 9, and even more preferably between 6 and 8.

[0038] Labyrinthuria can be cultured by subculturing at appropriate intervals depending on the genus and species of Labyrinthuria, the culture medium composition, and the culture conditions. For example, Labyrinthuria complete their logarithmic growth phase in about 2 days after the start of culture and enter the death phase in about 7 days. Therefore, it is preferable to subculture Labyrinthuria at intervals of 1 to 10 days, more preferably at intervals of 2 to 7 days, and even more preferably at intervals of 2 to 5 days. The culture time for Labyrinthuria can be set to an appropriate time depending on the genus and species of Labyrinthuria, the culture medium composition, the culture conditions, and the purpose of the culture. In particular, Aurantiochytrium algae of the Labyrinthuria genus are preferred because they are heterotrophic algae that inhabit brackish water areas and have the characteristic of assimilating nutrients in the water to produce lipids and accumulating them in the cells.

[0039] It is preferable to use strains of Aurantiochytrium algae that have a superior ability to produce the desired triglycerides. Such algal strains may be naturally collected and isolated, cloned after mutagenesis and screening, or established using genetic engineering techniques. For example, Aurantiochytrium Sp.SA-96, NIES-3737, Aurantiochytrium NB6-3, or Aurantiochytrium mh1959 strains are particularly preferred as microorganisms for the production of pentadecanoic acid triglyceride in the present invention because they have the property of accumulating large amounts of triglycerides containing the odd-chain fatty acid pentadecanoic acid (PDA) and triglycerides containing the highly unsaturated fatty acids docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA) within their cells.

[0040] The cultivation of the above-mentioned Aurantiochytrium algae is carried out by methods established in the art. That is, normal maintenance cultivation is carried out by seeding algae in a culture medium with appropriately prepared components and following standard procedures. The culture medium for cultivating Aurantiochytrium algae essentially contains salinity, a carbon source, and a nitrogen source. Generally, so-called GTY medium (artificial seawater 10-40 g / L, D(+) glucose 20-100 g / L, tryptone 10-60 g / L, yeast extract 5-40 g / L) is used for cultivating microalgae.

[0041] Carbon sources include sugars such as glucose, fructose, and sucrose. These carbon sources are added, for example, at a concentration of 20 to 120 g per liter of culture medium.

[0042] Aurantiochytrium algae are marine algae, and an appropriate amount of artificial seawater is added to the culture medium. Preferably, the artificial seawater is added so that the final salinity of the culture medium is about 10% (v / v) to about 100% (v / v) of seawater (salinity 3.4% (w / v)), for example, a salinity of about 1.0 to 3.0% (w / v).

[0043] Generally, various nitrogen sources can be added to the culture medium for microalgae, such as organic nitrogen (monosodium glutamate, urea), inorganic nitrogen (ammonium acetate, ammonium sulfate, ammonium chloride, sodium nitrate, ammonium nitrate), or biodigests (yeast extract, corn steep liquor, polypeptone, peptone, tryptone, etc.). In particular, cell extracts obtained by extracting liquid components from various animal cells are preferred as nitrogen sources to be added to the culture medium for Aurantiochytrium algae. When cells must be cultured on an industrial scale to obtain cultured cell products, the use of cell extracts, which are rich in nutrients such as amino acids, nucleic acids, vitamins, and minerals derived from cells and are available at low cost, is extremely advantageous.

[0044] However, as described above, using a culture medium prepared based on cell extracts significantly reduces the proportion of odd-chain fatty acids in the triglycerides produced by cultured algae. Therefore, cell extracts could not be used as a nitrogen source for the culture medium to efficiently produce the target product of the present invention. Accordingly, the inventors have already reported a method for producing triglycerides containing odd-chain fatty acids as the main component by culturing Aurantiochytrium algae in an algal culture medium prepared by adding strongly acid-treated cell extracts, and by dramatically increasing the production of odd-chain fatty acids compared to when untreated cell extracts were added (Japanese Patent Publication No. 2017-063633).

[0045] Furthermore, in a preferred embodiment of the present invention, the basic culture medium for cultivating Aurantiochytrium algae is prepared by adding 10-50 mM valine and 10-50 mM sodium propionate to a medium containing 2% or more glucose, 0.5-4% monosodium glutamate, 0.1-2% yeast extract, 1-3.3% sea salt, and 2-20% whey (animal or plant-based). Tofu whey (soybean whey) is preferred as the animal or plant-based whey. To this basic culture medium, 2% or more of a culture solution of Aurantiochytrium that has been pre-cultured at 20-30°C for 72 hours with 2% or more glucose, 0.5-4% monosodium glutamate, 0.1-2% yeast extract, 1-3.3% sea salt, and 2-20% whey (animal or plant-based) is added. Air is then passed through this Aurantiochytrium-added culture solution and it is gently stirred. The culture should be carried out at 20-30°C and maintained at a pH of 5.0-8.5 (using a 1.0 M NaOH solution for pH adjustment) for 48-200 hours. After culturing, Aurantiochytrium cells that have produced pentadecanoic acid triglyceride can be recovered by centrifugation (see WO2020 / 054804 pamphlet).

[0046] The pellets recovered from the culture medium obtained by the above method by centrifugation or filtration are dried by freeze-drying or drying by heating. Alternatively, the culture medium in which the algal cells are suspended after cultivation may be used directly in the triglyceride extraction step. Extraction may be carried out multiple times using different organic solvents. As organic solvents, a mixture of a polar solvent and a weakly polar solvent such as an n-hexane-ethanol mixed solvent, a chloroform-methanol mixed solvent, or an ethanol-diethyl ether mixed solvent can be used. The obtained extract is purified by methods known to those skilled in the art.

[0047] Methods for separating triglycerides employ fractionation techniques known to those skilled in the art. Separation and purification may be performed by utilizing various physicochemical properties of the triglyceride molecules to be fractionated, such as polarity, solubility in the solvent, melting point, specific gravity, and molecular weight, and column chromatography is preferably used. The conditions for the triglyceride separation means can be set by ordinary condition studies by those skilled in the art, depending on the composition of the triglyceride mixture and the type of triglyceride to be fractionated.

[0048] Algae of the genera Schizochytrium and Aurantiochytrium can synthesize and accumulate both odd-chain fatty acid triglycerides and highly unsaturated fatty acid triglycerides within their cells. Therefore, ethanol, hexane, or ethyl acetate is added to the obtained algal cells to extract the lipids, and the solvent is removed by distillation to obtain algal lipids. By allowing these lipids to stand at 5°C, pentadecanoic acid triglyceride can be precipitated. The composition of the purified pentadecanoic acid triglyceride "PdATG" can be analyzed by HPLC-MS, HPLC, gas chromatography, etc.

[0049] Algae of the genus Aurantiochytrium can synthesize and accumulate both odd-chain fatty acid triglycerides and highly unsaturated fatty acid triglycerides within their cells. Therefore, after extracting lipids by adding hexane or ethyl acetate to the obtained Aurantiochytrium cells, the unsaturated fatty acids are oxidatively decomposed by adding hydrogen peroxide to this lipid solution or by passing ozone through it. After the reaction is complete, oxides are removed using sodium bicarbonate and sodium carbonate or ion exchange resin to obtain pentadecanoic acid triglyceride "PdATG". The composition of the purified pentadecanoic acid triglyceride "PdATG" can be analyzed by HPLC-MS, HPLC, gas chromatography, etc.

[0050] (Endoplasmic reticulum stress inhibitor) The first aspect of the present invention relates to an endoplasmic reticulum stress inhibitor, which includes a formulation that suppresses glomerular epithelial cell death caused by the accumulation of abnormal proteins in the endoplasmic reticulum. Here, glomerular epithelial cell death encompasses necrosis and apoptosis of glomerular epithelial cells. This includes mitigating, reducing, or eliminating cell death, suppressing the progression of cell death, and preventing or preventing it. It can be used to prevent, slow the progression of, and / or improve disorders (diseases and age-related changes) that become apparent due to glomerular epithelial cell death caused by endoplasmic reticulum stress, such as kidney diseases including CKD, tubulointerstitial nephritis, hyperuricemia, gout, nephrolithiasis, and systemic vascular diseases (cardiovascular diseases) such as foot gangrene, and is useful as a pharmaceutical for this purpose.

[0051] (Pharmaceuticals) Furthermore, the term "pharmaceutical" refers to a therapeutic drug used to prevent, slow the progression of, and / or improve symptoms in patients with disorders and related disorders that manifest as glomerular epithelial cell death as described above, by suppressing endoplasmic reticulum stress.

[0052] The compositions or pharmaceuticals produced according to the present invention are effective not only in humans but also in mammals, including livestock such as cattle, horses, pigs, and goats, as well as pet animals such as dogs and cats.

[0053] The composition or pharmaceutical product according to the present invention may contain only the compound of formula (I) as an active ingredient, or it may contain other components as long as they do not inhibit the glomerular epithelial cell damage inhibitory effect. The other components may be, for example, conventionally used therapeutic or prophylactic drugs. Therefore, in a further embodiment, the endoplasmic reticulum stress inhibitor of this embodiment provides a pharmaceutical composition for preventing and improving glomerular epithelial cell damage diseases.

[0054] Furthermore, the compositions or pharmaceuticals based on the present invention can be administered orally and can be prepared in dosage forms suitable for oral administration, such as granules, powders, tablets (including sugar-coated tablets), pills, capsules, syrups, emulsions, and suspensions. These formulations can be manufactured using pharmaceutically acceptable carriers by methods commonly practiced in the art. Examples of pharmaceutically acceptable carriers include excipients, binders, diluents, additives, fragrances, buffers, thickeners, colorants, stabilizers, emulsifiers, dispersants, suspending agents, and preservatives.

[0055] While not particularly limited, more specifically, when manufacturing pharmaceuticals using pentadecanoic acid triglyceride represented by the above formula (I), any auxiliary agents such as sugars like dextrin and starch; proteins like gelatin, soy protein, and corn protein; amino acids like alanine, glutamine, and isoleucine; polysaccharides like cellulose and acacia gum; and oils and fats like soybean oil and medium-chain triglyceride can be added to formulate the product into any dosage form.

[0056] The amount of pentadecanoic acid triglyceride represented by the above formula (I) in the pharmaceutical product according to the present invention is not particularly limited, but it is preferable to adjust it so that the daily intake of pentadecanoic acid triglyceride for adults, which is the concentration that shows efficacy, is about 5 to 1000 mg per day.

[0057] Furthermore, the composition or pharmaceutical product according to the present invention is not limited to an oral administration form, but can also be administered parenterally, for example, in the form of an injection or intravenous solution. In this case as well, it can be formulated using pharmaceutically acceptable excipients, carriers, etc., by methods commonly used in the art.

[0058] (food) The food according to the third aspect of the present invention contains pentadecanoic acid triglyceride represented by the above formula (I) as an active ingredient and can be consumed for a long period of time as a preventive food or drink even before the onset of CKD, making it useful as a health food for that purpose. Pentadecanoic acid, which constitutes PdATG, has been reported to be present in small amounts in the meat of cattle, pigs, chickens, and sheep, as well as in fish living in rivers and the sea, and in edible parts of mushrooms, and it is also presumed that PdATG is present in trace amounts and has a high level of safety based on many years of experience in consumption.

[0059] Therefore, the food of this embodiment is useful as a health food to be taken for health promotion. Here, "health food" refers to food and beverages intended to be used to prevent, slow the progression of, alleviate or improve symptoms such as swelling of the fingers, face, shins and insteps of the feet, changes in urine, difficulty urinating, frequent urination, abnormally foamy urine, blood in the urine and a brownish color, feeling heavy, sluggish, easily fatigued, and cystitis, and is a broad term for "health food" that meets the safety and effectiveness standards set by the government, including functional foods, nutrient functional foods, and foods for specified health uses under the "Health Functional Food System".

[0060] When manufacturing food products using pentadecanoic acid triglyceride represented by the above formula (I), any auxiliary agents such as sugars like dextrin and starch; proteins like gelatin, soy protein, and corn protein; amino acids like alanine, glutamine, and isoleucine; polysaccharides like cellulose and acacia gum; and oils and fats like soybean oil and medium-chain triglyceride can be added to formulate the product into any dosage form.

[0061] Furthermore, while the amount of pentadecanoic acid triglyceride represented by formula (I) in the food of the present invention is not particularly limited, it is preferable to adjust it so that the daily intake of pentadecanoic acid triglyceride for adults is approximately 1 to 100 mg, taking into consideration the general intake of the food to which it is added.

[0062] Specific examples of the above-mentioned foods include, for example, beverages such as soft drinks, carbonated drinks, nutritional drinks, fruit drinks, and lactic acid drinks (including concentrated liquids and powders for adjusting these beverages); frozen desserts such as ice cream, ice sherbet, and shaved ice; noodles such as soba, udon, vermicelli, gyoza wrappers, shumai wrappers, Chinese noodles, and instant noodles; confectionery such as candy, candy, gum, chocolate, snacks, biscuits, jelly, jam, cream, and baked goods; processed seafood and livestock products such as kamaboko, ham, and sausage; dairy products such as processed milk and fermented milk; oils and processed oils such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, and dressings; seasonings such as sauces and dips; health and nutritional supplements in various forms such as tablets and granules; and other items such as soups, stews, salads, side dishes, and pickles.

[0063] The food according to the present invention may contain various food additives, such as antioxidants, flavorings, various esters, organic acids, organic acid salts, inorganic acids, inorganic acid salts, inorganic salts, pigments, emulsifiers, preservatives, seasonings, sweeteners, acidulants, fruit juice extracts, vegetable extracts, nectar extracts, pH adjusters, and quality stabilizers, either alone or in combination.

[0064] In the food according to the present invention, the concentration of pentadecanoic acid triglyceride as solid content is approximately 0.00001 to 100% by mass (hereinafter expressed in %), preferably approximately 0.0005 to 50%, to obtain good usability and effects.

[0065] The present invention will now be described in more detail with reference to examples, but the present invention is not limited in any way to these examples. In the following examples, the unit % in the numerical values ​​indicating the amount of each component added means mass %. [Examples]

[0066] (Manufacturing Example 1) Production of pentadecanoate triglyceride using aurantiochytrium Aurantichytrium mh1959 strain (purchased from Professor Masahiro Hayashi, Faculty of Agriculture, Miyazaki University) was pre-cultured for 72 hours at 25°C in a medium containing 3.6% glucose, 0.5% monosodium glutamate, 0.2% yeast extract, 1% sea salt, and 10% whey. This was added to the following basic medium to a concentration of 2%, aerated, and gently mixed. 1 kg of basic medium was prepared by adding 50 mM valine and 25 mM sodium propionate to a medium containing 3.6% glucose, 0.5% monosodium glutamate, 0.2% yeast extract, 1% sea salt, and 10% whey. The culture was maintained at 25°C and pH 7.40-7.75 (1.0 M NaOH solution was used for pH adjustment) for 72-96 hours.

[0067] After culturing, the algae were centrifuged at 3000 rpm for 15 minutes to collect approximately 20 g of algae. Hexane or ethyl acetate was added to the obtained 20 g of Aurantichytrium algae to extract the lipids. Hydrogen peroxide was added to the extracted lipid solution (water was added if necessary), and ozone was passed through at room temperature. After the reaction was complete, oxides were removed using sodium bicarbonate and sodium carbonate or ion exchange resin to obtain 2 g of a mixture of pentadecanoic acid triglycerides that precipitated as the temperature decreased.

[0068] (Compositional analysis of pentadecanoic acid triglyceride) To the lipid containing pentadecanoic acid triglyceride obtained in Production Example 1, 0.50 mL of 14% BF3-methanol and 0.25 mL of methyl acetate were added, and the mixture was heated at 70°C for 30 minutes to obtain the fatty acid methyl ester (FAME). Exactly 1.0 mL of n-hexane and 5 mL of physiological saline were added to the reaction mixture and mixed vigorously. The mixture was centrifuged at 2800 rpm for 10 minutes, and the n-hexane layer was used as the sample for gas chromatography.

[0069] The above samples were analyzed using a Shimadzu GC-2025 gas chromatograph. The analysis conditions involved using an Agilent J&W GC column DB-23 (30m × 0.25mm), injecting 1 μL of the sample, and detecting it with a carrier gas (He, 14 psi) using a flame ionization detector (FID). FAME molecular species were identified based on the retention time of fatty acid methyl ester standards (GL Sciences). The fatty acid composition was determined from the area ratio. The determined composition is expressed as a mass ratio. The proportion of odd-chain fatty acids was calculated by multiplying the total fatty acid amount by the proportion (%) of odd-chain fatty acids (C13, C15, C17). The results are shown in Table 1 below.

[0070] [Table 1]

[0071] As shown in Table 1, the content of odd-chain fatty acids in the triglycerides obtained in Production Example 1 was 68.3% by mass. Furthermore, it was found that the fatty acids mainly consisted of triglycerides composed of pentadecanoic acid residues (C15) and palmitic acid residues (C16).

[0072] (Mass spectrometry of pentadecanoate triglyceride) The lipids containing pentadecanoic acid triglyceride obtained in Production Example 1 were analyzed by mass spectrometry using a Thermo Fischer Orbitrap Exactive Plus mass spectrometer (AMR DART ion source). As a result, from the fragment composition of the main mass spectral peaks, it was found that the pentadecanoic acid triglyceride obtained in Production Example 1 is a triglyceride mixture mainly consisting of triglycerides formed only from pentadecanoic acid residues (C15) and triglycerides containing two units of pentadecanoic acid residues (C15) and one unit of palmitic acid residue (C16).

[0073] (Example 1) Investigation of glomerular function using a CKD animal model with PdATG To examine the effect of PdATG, a solution of pentadecanoic acid triglyceride obtained in Production Example 1 dissolved in ethanol was used as a test substance, and the following experiment was conducted.

[0074] ·Test method For the CKD animal model, male C57BL / 6JJmsSlc mice were used, and 2 / 3 of the left kidney was removed at 8 weeks of age, followed by total resection of the right kidney at 9 weeks of age to prepare 5 / 6 nephrectomized mice (Nx mice). Sham-operated mice (Sham group) only underwent skin and muscle incisions. Renal function was evaluated based on serum urea nitrogen (BUN) levels and serum creatinine (Cre) levels. Hematoxylin-eosin staining was used for histological verification of renal glomeruli.

[0075] ·Results Pentadecanoic acid triglyceride (0.2 g / L) was suspended in drinking water for animals, and Nx mice were allowed to ingest it orally for 8 weeks. Time-dependent changes in body weight gain, water intake, and food intake were observed, and no changes due to pentadecyl administration were observed in any of these parameters. A log-rank test was also performed for survival rate, but no significant difference was observed.

[0076] ·Effect of chronic administration of PdATG on renal function decline <Effect on glomerular area> As shown in Figures 1(A) and (B), the PdATG administration group showed a tendency to reduce the area per glomerulus, which was increased by nephrectomy treatment, as compared with the water administration group.

[0077] <Effect on CRE and BUN> As shown in Figures 2(A) and (B), the BUN level and Cre level, which indicate the renal function of Nx mice, were significantly increased as compared with the values of sham-operated mice, and pentadecanoic acid triglyceride remarkably suppressed this increase. On the other hand, administration of pentadecanoic acid triglyceride did not affect the increase in glomerular area that occurs in Nx mice.

[0078] Based on the above findings, it was suggested that pentadecanoate triglyceride has the effect of preventing the exacerbation of uremia by partially suppressing the progression of renal dysfunction in CKD model mice. Therefore, it was confirmed that pentadecanoate triglyceride is useful in the prevention and treatment of kidney diseases involving impaired renal function. [Industrial applicability]

[0079] The PdATG according to the present invention can be used to prevent, slow the progression of, and / or improve disorders (diseases and age-related changes) that manifest due to glomerular epithelial cell death caused by endoplasmic reticulum stress, such as tubulointerstitial nephritis, hyperuricemia, gout, nephrolithiasis, and systemic vascular diseases (cardiovascular diseases) such as foot gangrene, and the present invention provides an endoplasmic reticulum stress preventive and inhibitory agent that has no or few side effects.

Claims

1. The following formula (I): 【Chemistry 1】 (In the formula, R 1 , R 2 and R 3 A triglyceride represented by formula (I), in which R1, R2, and R3 are all pentadecanoic acid residues, and a triglyceride in formula (I), in which any two of R1, R2, and R3 are pentadecanoic acid residues and the other one is a myristic acid or palmitic acid residue, is provided as an active ingredient in a preventive and ameliorative agent for at least one disease selected from the group consisting of kidney disease, tubulointerstitial nephritis, hyperuricemia, gout, and nephrolithiasis.

2. The preventive and ameliorative agent according to claim 1, wherein the triglyceride of formula (I) is derived from algae of the genus Aurantiochytrium or Schizochytrium.

Citation Information

Patent Citations

  • Fatty alcohols and fatty acid esters useful in treating inflammation

    JP2004525180A

  • Medium-chain fatty acids and glycerides as renal protective agents

    JP2011502174A

  • Method for producing triglyceride containing microorganism-derived odd number-fatty acid or higher unsaturated fatty acid

    JP2016089025A

  • Pharmaceutical composition for prevention or treatment of kidney damage

    JP2019214557A

  • Pharmaceutical composition for prevention or treatment of kidney damage

    JP2019214558A